Cantor Highlights Cybin's (CYBN) CYB003’s Potential to Shift MDD Treatment
Tweet Send to a Friend
Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Cybin Inc. (NYSE: CYBN).The analyst commented, "We continue to highlight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


